Vanguard Group Inc. Grows Stake in USANA Health Sciences, Inc. (NYSE:USNA)

Vanguard Group Inc. increased its stake in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 2.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,567,182 shares of the company's stock after buying an additional 38,533 shares during the quarter. Vanguard Group Inc. owned about 8.19% of USANA Health Sciences worth $91,853,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. American Century Companies Inc. lifted its stake in USANA Health Sciences by 2.3% during the third quarter. American Century Companies Inc. now owns 135,996 shares of the company's stock worth $7,971,000 after purchasing an additional 3,028 shares during the last quarter. Comerica Bank bought a new stake in USANA Health Sciences during the third quarter worth $316,000. Jacobs Levy Equity Management Inc. lifted its stake in USANA Health Sciences by 2.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 90,659 shares of the company's stock worth $5,314,000 after purchasing an additional 2,168 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in USANA Health Sciences by 28.5% during the third quarter. The Manufacturers Life Insurance Company now owns 5,933 shares of the company's stock worth $348,000 after purchasing an additional 1,316 shares during the last quarter. Finally, Royal Bank of Canada lifted its stake in USANA Health Sciences by 17.5% during the third quarter. Royal Bank of Canada now owns 4,936 shares of the company's stock worth $289,000 after purchasing an additional 734 shares during the last quarter. Institutional investors and hedge funds own 54.25% of the company's stock.

USANA Health Sciences Stock Performance

Shares of USNA traded up $0.15 during trading hours on Friday, reaching $45.97. The stock had a trading volume of 145,602 shares, compared to its average volume of 94,118. USANA Health Sciences, Inc. has a 12 month low of $44.01 and a 12 month high of $69.60. The stock has a market capitalization of $884.46 million, a PE ratio of 13.93, a PEG ratio of 1.40 and a beta of 0.91. The company's 50-day moving average is $48.43 and its two-hundred day moving average is $50.22.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its earnings results on Tuesday, February 6th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.35. The business had revenue of $221.08 million during the quarter, compared to analyst estimates of $206.70 million. USANA Health Sciences had a return on equity of 13.49% and a net margin of 6.93%. Equities analysts anticipate that USANA Health Sciences, Inc. will post 2.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Robert A. Sinnott sold 3,945 shares of the firm's stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $46.55, for a total transaction of $183,639.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other USANA Health Sciences news, insider David Mulham Mulham sold 4,311 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $47.76, for a total transaction of $205,893.36. Following the completion of the sale, the insider now directly owns 7,825 shares in the company, valued at approximately $373,722. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Robert A. Sinnott sold 3,945 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $46.55, for a total value of $183,639.75. The disclosure for this sale can be found here. Insiders sold a total of 24,807 shares of company stock valued at $1,200,791 in the last three months. Insiders own 0.33% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. StockNews.com upgraded USANA Health Sciences from a "buy" rating to a "strong-buy" rating in a research note on Friday, January 12th. DA Davidson dropped their price target on USANA Health Sciences from $53.00 to $48.00 and set a "neutral" rating for the company in a research note on Thursday, February 22nd.

USANA Health Sciences Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.